| (210) | Number of the EPO application | 18213309 |
| (220) | Filing date of the EPO application | 2015.12.23 |
| (80) | EPO patent specification publication (B) | EPB nr. 34/2021, 2021.08.25 |
| (110) | EPO patent number | 3521282 |
| (21) | Number of the application | e 2020 0223 |
| (71) | Name(s) of applicant(s), code of the country | Gilead Sciences, Inc., US;
Institute of Organic Chemistry
and Biochemistry AS CR, V.V.I., CZ; |
| (72) | Name(s) of inventor(s), code of the country | JANSA Petr, US;
SIMON Petr, CZ;
LANSDON Eric, US;
HU Yunfeng Eric, US;
BASZCZYNSKI Ondrej, CZ;
DEJMEK Milan, CZ;
MACKMAN Richard L., US; |
| (73) | Name(s) of owner(s), code of the country | GILEAD Sciences Inc., US;
INSTITUTE of Organic Chemistry
and Biochemistry AS CR V.V.I., CZ; |
| (54) | Title of the invention | QUINAZOLINE DERIVATIVES USED TO TREAT HIV |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | C07D 401/12 (2006.01.01); C07D 239/94 (2006.01.01); A61K 31/517 (2006.01.01); A61P 31/18 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2020.04.30 |
| (30) | Priority | 201462096748 P, 2014.12.24, US |